Active substance
Results for the substance lanadelumab
3 results
About this active substance
Lanadelumab is a monoclonal antibody used to prevent recurrent attacks of hereditary angioedema (HAE) in patients with this rare condition. It works by inhibiting the activity of plasma kallikrein, an enzyme involved in triggering angioedema episodes.
The medication is administered as subcutaneous injections, usually once every two weeks, as directed by a doctor. The treatment is effective in reducing the frequency and severity of angioedema attacks.
Side effects may include injection site reactions, headaches, fatigue, or upper respiratory tract infections. In rare cases, severe allergic reactions may occur.
Patients should strictly follow their doctor's instructions and inform them about any other medications they are taking. Pregnant or breastfeeding women should consult a specialist before use.
The medication is administered as subcutaneous injections, usually once every two weeks, as directed by a doctor. The treatment is effective in reducing the frequency and severity of angioedema attacks.
Side effects may include injection site reactions, headaches, fatigue, or upper respiratory tract infections. In rare cases, severe allergic reactions may occur.
Patients should strictly follow their doctor's instructions and inform them about any other medications they are taking. Pregnant or breastfeeding women should consult a specialist before use.
-
-
TAKHZYRO 300mg solution for injection in pre-filled pen TAKEDA ORIGINAL MEDICINE
-
TAKHZYRO 150mg solution for injection in pre-filled syringe TAKEDA ORIGINAL MEDICINE